Spyre Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:SYRE) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -75.78 M-53.72 M-80.14 M-99.91 M-157.41 M-169.25 M -185.63 M Cash from investing activities -7.6 M-22.62 M57.01 M-108.39 M-353.29 M-143.47 M -86.83 M Cash from financing activities 154.51 M1.39 M42.68 M361.08 M410.91 M309.02 M 321.15 M Free cash flow -75.78 M-53.72 M-80.14 M-99.91 M-157.41 M-169.25 M -185.63 M

News

SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis - Slideshow (NASDAQ:SYRE) 2026-04-14

Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms (NASDAQ:SYRE)

Leerink reiterates Spyre stock Outperform on faster trial timeline

Spyre Therapeutics stock remains top 2026 pick at Guggenheim

Spyre Therapeutics, Inc. (SYRE) Presents at Leerink Global Healthcare Conference 2026 Transcript

3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts - TipRanks.com

Spyre Therapeutics stock hits 52-week high at 42.93 USD

Spyre Therapeutics stock hits 52-week high at 35.82 USD

Drugmakers turn to AI to speed trials, regulatory submissions